Lisa Wilson | Investor Relations |
Scott Tarriff | President and Chief Executive Officer |
Brian Cahill | Chief Financial Officer |
Brandon Folkes | Cantor Fitzgerald |
Lachlan Hanbury-Brown | William Blair |
David Amsellem | Piper Sandler |
Good morning, everyone. My name is Todd, and I'll be your conference operator. At this time, I'd like to welcome everyone to Eagle Pharmaceuticals Fourth Quarter and Full-Year 2022 Financial Results [Technical Difficulty]. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer period.